BDX Becton Dickinson
Health Care · Health Care Equipment · close $191.75 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
Becton Dickinson (BDX) has a ThetaGrade House Rating of 47/100 (grade D), ranking #30 of 150 in Health Care. Its strongest pillars are profitability (64) and cash flow (64); its weakest is balance sheet (25). TTM revenue growth is 13.1% and operating margin 10.3%.
Data as of .
Analyst sentiment
weight 7.5% · 50| Consensus score (1–5) (3.8%) | derived | 26 |
| 90-day net rating shift (3.8%) | derived | 90 |
Growth
weight 30.83% · 42| Revenue growth YoY (TTM) (12.3%) | 13.1% | 60 |
| EPS growth YoY (TTM) (12.3%) | -39.6% | 18 |
| Revenue acceleration (6.2%) | 0.2% | 55 |
Profitability
weight 18.5% · 64| Operating margin (9.9%) | 10.3% | 43 |
| 4Q gross-margin change (8.6%) | 2.2% | 87 |
Balance sheet
weight 18.5% · 25| Net debt / EBITDA (9.9%) | 2.84× | 30 |
| Current ratio (4.9%) | 0.87 | 4 |
| Interest coverage (3.7%) | 3.77× | 38 |
Cash flow
weight 12.33% · 64| FCF margin (6.2%) | 12.2% | 47 |
| FCF yield (6.2%) | 5.1% | 80 |
Valuation
weight 12.33% · 46| P/E (inverted) (6.2%) | 57.93× | 18 |
| EV/Sales (inverted) (6.2%) | 2.93× | 74 |
Technicals (EOD)
| RSI(14) | 63.7 |
| EMA 9 / 21 | 187.61 / 184.75 · crossed up 5d ago |
| 200-day SMA | 169.98 |
| Volume vs 20d avg | 0.78× |
| 20-day return | 5.7% |
Exit-rule monitor
- EXITRating break: House Rating below 60
Data source per metric (SEC XBRL tag or derivation): Revenue: Revenues · Gross profit: Revenue − CostOfGoodsAndServicesSold · Operating income: OperatingIncomeLoss · Interest expense: InterestExpense · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).
Get rating changes like BDX's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is BDX's House Rating?
- BDX scores 47 out of 100 (grade D) as of 2026-10-16, ranking #30 of 150 Health Care stocks we cover.
- What do analysts say about BDX?
- ThetaGrade's analyst-sentiment pillar for BDX scores 50/100 against its sector peers, which we read as mixed. This is our own derived score; we do not republish individual analyst ratings, counts or targets.
- When does BDX report earnings next?
- BDX's next earnings report is estimated for about 2026-11-05 (window 2026-10-29 to 2026-11-12), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
- Is BDX a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology